Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An announcement from Shield Therapeutics ( (GB:STX) ) is now available.
Shield Therapeutics PLC announced the closure of its RetailBook Offer, raising gross proceeds of £96,715.83 through the issuance of shares at 3.0 pence per share. Overall, the combined RetailBook Offer and Subscription are expected to generate approximately £7.79 million, pending approval of resolutions at the upcoming General Meeting. Successful passage of these resolutions will lead to the admission of shares for trading on AIM, bolstering the company’s financial position and potentially enhancing its market presence.
More about Shield Therapeutics
Shield Therapeutics PLC is a company operating in the pharmaceutical industry, primarily focused on developing and commercializing treatments for iron deficiency. The company aims to address unmet medical needs and improve patient outcomes through its innovative product offerings.
YTD Price Performance: -59.33%
Average Trading Volume: 2,718,151
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £21.31M
See more insights into STX stock on TipRanks’ Stock Analysis page.
